CLOPIDOGREL: THE FUTURE CHOICE FOR PREVENTING PLATELET ACTIVATION DURING CORONARY STENTING?
- 1 August 1999
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 40 (2) , 107-111
- https://doi.org/10.1006/phrs.1999.0478
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) InhibitorsBlood, 1998
- Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptorsEuropean Journal of Pharmacology, 1998
- P2X1 Purinoceptor in Human PlateletsJournal of Biological Chemistry, 1998
- Molecular Basis for ADP-induced Platelet ActivationJournal of Biological Chemistry, 1998
- GPIIb/IIIa Antagonists: Pathophysiologic and Therapeutic Insights from Studies of c7E3 FabThrombosis and Haemostasis, 1997
- Stents for intracoronary placement: Current status and future directionsJournal of the American College of Cardiology, 1996
- Subacute stent thrombosis: Evolving issues and current conceptsJournal of the American College of Cardiology, 1996
- Clinical Pharmacokinetics of TiclopidineClinical Pharmacokinetics, 1994
- Rapid and Selective Inhibition of Platelet Aggregation and Thromboxane Formation by Intravenous Low Dose Aspirin in ManClinical Science, 1993
- TiclopidineDrugs, 1987